AJMC May 7, 2022
Next-generation sequencing identified different molecular profiles of pediatric and adult sarcomas among Chinese patients.
Next-generation sequencing (NGS) identified different molecular profiles of pediatric and adult sarcomas, including actionable gene mutations that can be targeted by FDA-approved drugs. Findings were reported in an abstract presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting.
With over 100 subtypes, pediatric sarcomas represent approximately 12% of all pediatric cancers. Researchers highlighted that some molecular detection techniques can be used to assist the diagnosis and treatment of pediatric sarcoma, but this remains challenging due to overlapping morphological features and limited biopsy specimens.
Recent technological innovations in genomic profiling with NGS has shown its effectiveness in identifying biomarkers, prognosis, and response to therapy...
Today's Sponsors
Today's Sponsor